Geron (NASDAQ:GERN) Trading Up 4.6%

Geron Co. (NASDAQ:GERN)’s stock price traded up 4.6% during trading on Wednesday . The company traded as high as $3.71 and last traded at $3.66. 2,995,182 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 11,080,196 shares. The stock had previously closed at $3.50.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Geron in a research report on Thursday, April 11th. The Goldman Sachs Group increased their target price on shares of Geron from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $6.00 target price on shares of Geron in a research report on Wednesday, April 10th.

Geron Price Performance

The company has a market cap of $2.07 billion, a price-to-earnings ratio of -11.52 and a beta of 0.62. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.14. The company’s 50 day moving average price is $2.86 and its 200 day moving average price is $2.29.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Geron had a negative net margin of 77,691.14% and a negative return on equity of 63.33%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. During the same quarter last year, the business earned ($0.10) earnings per share. The business’s revenue for the quarter was down 77.7% compared to the same quarter last year. Equities research analysts forecast that Geron Co. will post -0.34 earnings per share for the current year.

Institutional Trading of Geron

Large investors have recently modified their holdings of the business. Rafferty Asset Management LLC grew its position in shares of Geron by 43.6% in the third quarter. Rafferty Asset Management LLC now owns 1,902,266 shares of the biopharmaceutical company’s stock valued at $4,033,000 after purchasing an additional 577,422 shares during the last quarter. Jump Financial LLC grew its position in shares of Geron by 922.4% in the third quarter. Jump Financial LLC now owns 831,308 shares of the biopharmaceutical company’s stock valued at $1,762,000 after purchasing an additional 750,001 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Geron by 3.4% in the third quarter. Wellington Management Group LLP now owns 10,405,626 shares of the biopharmaceutical company’s stock valued at $22,060,000 after purchasing an additional 342,493 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Geron during the third quarter worth approximately $29,000. Finally, Nan Fung Group Holdings Ltd boosted its position in Geron by 94.2% during the third quarter. Nan Fung Group Holdings Ltd now owns 753,550 shares of the biopharmaceutical company’s stock worth $1,598,000 after acquiring an additional 365,550 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.